The estimated intrinsic value of Garden Stage Limited Ordinary Shares (GSIW) using a Book Value × Return on Equity (P/B × ROE) model is $-0.45 (based on the recommended P/B × ROE method), compared to the current stock price of $22.30. This suggests the stock may be overvalued by 102.0% relative to its intrinsic value.

For banks and financial institutions, traditional DCF models are unreliable because cash flows are heavily influenced by lending and deposit activities. Instead, SharesGrow uses a Book Value × ROE model: Intrinsic Value = Book Value Per Share × (Return on Equity ÷ Cost of Equity) × Growth Adjustment. This approach values the firm based on how efficiently it generates returns on shareholders' equity relative to its cost of capital — the standard methodology used by institutional investors for bank valuation.

The valuation uses a CAPM-derived discount rate of 7.73% (CAPM-derived from beta of 2.48).

⚠ Why is the Intrinsic Value (IV) not available for this stock?
Our Discounted Cash Flow (DCF) model cannot produce a meaningful Intrinsic Value (IV) for Garden Stage Limited Ordinary Shares (GSIW) at this time. The DCF model requires positive cash flows as a starting point for projecting future value.

• All cash flow metrics are negative. Operating Cash Flow (OCF), Free Cash Flow (FCF), and Net Income (NI) are all currently negative. The company is burning cash across all measures, which means there is no positive cash flow to discount. This is common for pre-revenue biotechs, early-stage growth companies, and turnaround situations.
• No analyst earnings estimates available. Without forward-looking Earnings Per Share (EPS) estimates from analysts, we cannot derive a meaningful growth rate for the Discounted Cash Flow (DCF) projection. The model falls back to historical growth, which may be unreliable for companies undergoing significant change.